Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06352632
Registration number
NCT06352632
Ethics application status
Date submitted
1/04/2024
Date registered
2/04/2024
Date last updated
19/04/2024
Titles & IDs
Public title
A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke
Query!
Scientific title
A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)
Query!
Secondary ID [1]
0
0
ACT-GLOBAL_Master
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ACT-GLOBAL
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Stroke
0
0
Query!
Condition category
Condition code
Stroke
0
0
0
0
Query!
Haemorrhagic
Query!
Stroke
0
0
0
0
Query!
Ischaemic
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Standard-dose intravenous tenecteplase
Treatment: Drugs - Low-dose intravenous tenecteplase
Other interventions - No intravenous tenecteplase
Other interventions - Conservative Blood Pressure Control
Other interventions - Moderate Blood Pressure Control
Other interventions - Intensive Blood Pressure Control
Other interventions - Placebo
Treatment: Drugs - NoNO-42
Experimental: IV thrombolysis domain - This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design to optimize the use of intravenous Tenecteplase in participants with Acute Ischemic Stroke.
Experimental: Blood Pressure domain - Third Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED3/MT) as a domain of ACT-GLOBAL to compare three BP lowering management strategies, that of conservative, moderate and intensive BP lowering in patients with Acute Ischaemic Stroke admitted to participating hospitals who has an elevated SBP after reperfusion therapy via Endovascular Thrombectomy, and reliably determine, which approach leads to improved functional outcome.
Locally available and approved i.v. BP lowering agents can be used in this domain.
Experimental: ACT-42 domain - This domain has a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive design and aim to determine the efficacy and safety of NoNO-42 in participants with Acute Ischaemic Stroke selected for thrombolysis with or without Endovascular Thrombectomy.
Treatment: Drugs: Standard-dose intravenous tenecteplase
Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation
Treatment: Drugs: Low-dose intravenous tenecteplase
Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation
Other interventions: No intravenous tenecteplase
No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)
Other interventions: Conservative Blood Pressure Control
No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
Other interventions: Moderate Blood Pressure Control
SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
Other interventions: Intensive Blood Pressure Control
SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
Other interventions: Placebo
100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.
Treatment: Drugs: NoNO-42
NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
modified Rankin scale (mRS) scores
Query!
Assessment method [1]
0
0
The mRS is a 7-outcome ordered categorical scale that assesses functional neurological status after stroke. It is not intended for use as a measure of historical functional status. It is well accepted as a standard outcome around the world in the stroke community, by patients and by regulatory authorities. The seven values and the clinical summary of the individual scores are summarized in the following:
0 = No symptoms
= No significant disability; able to carry out all usual activities
= Slight disability; can look after own affairs, but unable to carry out all previous activities
= Moderate disability; require some help
= Moderately severe disability; unable to attend to own bodily needs without assistance
= Severe disability; bedridden and requiring constant nursing care and attention
= Dead
Query!
Timepoint [1]
0
0
Platform level time frame: 90 days in Ischaemic Stroke State; Domain specific time frame may differ (details will be included in domain-specific registration)
Query!
Secondary outcome [1]
0
0
Excellent functional neurological outcome
Query!
Assessment method [1]
0
0
Excellent functional neurological outcome means modified Rankin scale (mRS) scores 0-1. The minimum mRS is 0 (no symptoms) while the maximum mRS is 6 (death). The higher the mRS score is the worse outcome is.
Query!
Timepoint [1]
0
0
Platform level time frame: 90 days in Ischaemic Stroke State; Domain specific time frame may differ (details will be included in domain-specific registration)
Query!
Secondary outcome [2]
0
0
Independent functional neurological outcome
Query!
Assessment method [2]
0
0
Independent functional neurological outcome means modified Rankin scale (mRS) scores 0-2. The minimum mRS is 0 (no symptoms) while the maximum mRS is 6 (death). The higher the mRS score is the worse outcome is.
Query!
Timepoint [2]
0
0
Platform level time frame: 90 days in Ischaemic Stroke State; Domain specific time frame may differ (details will be included in domain-specific registration)
Query!
Secondary outcome [3]
0
0
Health Related Quality of Life
Query!
Assessment method [3]
0
0
Health Related Quality of Life based on EuroQol 5 Dimension 5 Level (EQ-5D-5L).The EQ-5D-5L is a generic instrument for describing and valuing health. It is based on a descriptive system that defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five response categories corresponding to: no problems, slight, moderate, severe and extreme problems.
Query!
Timepoint [3]
0
0
Platform level time frame: 90 days in Ischaemic Stroke State; Domain specific time frame may differ (details will be included in domain-specific registration)
Query!
Eligibility
Key inclusion criteria
Platform
1. Age ≥18 years
2. Clinical diagnosis of stroke
Platform
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
There are no platform level exclusion criteria
Each state and domain will specify additional inclusion and exclusion criteria in the
respective Domain-Specific Registration. Patients who fulfill the overall platform criteria
will be assessed for enrollment into each active domain.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Factorial
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
1/04/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/04/2034
Query!
Actual
Query!
Sample size
Target
20000
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
The George Institute
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
University of Calgary
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Berry Consultants
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019.
There remains an urgent need for interventions that improve outcomes which can be implemented
with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage,
randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s
associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL
multiple questions will be evaluated simultaneously and sequentially as data accrues and can
evaluate interactions between different treatment options.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06352632
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Craig Anderson, MD, PhD
Query!
Address
0
0
The George Institute
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Xiaoying Chen, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61280524549
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06352632
Download to PDF